Extraintestinal complications of inflammatory bowel disease

  • Ad A. van Bodegraven
  • Ben A. C. Dijkmans
  • Paul Lips
  • Tom J. Stoof
  • A. Salvador Peña
  • Stephan G. M. Meuwissen

Opinion statement

  • Extraintestinal complications of inflammatory bowel disease (IBD) are often secondary to the underlying disease. Therefore, the first priority is to get active IBD into remission with medications, since surgery for IBD is not indicated for the treatment of extraintestinal complications.

  • Symptoms of extraintestinal complications usually can be treated with simple agents; the treatment of patients with refractory symptoms and the use of more complex drug regimens should be done in cooperation with specialists on affected organ systems.

  • Careful consideration of prescribed drugs is necessary because they may negatively influence the course of IBD.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Rankin GB: Extraintestinal and systemic manifestations of inflammatory bowel disease. Med Clin North Am 1990, 74:39–50.PubMedGoogle Scholar
  2. 2.
    Jahnsen J, Falch JA, Aadland E, Mowinckel P: Bone mineral density is reduced in patients with Crohn’s disease, but not in patients with ulcerative colitis. Gut 1997, 40:313–319.PubMedGoogle Scholar
  3. 3.
    Abitbol V, Roux C, Chaussade S, et al.: Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995, 108:417–422.PubMedCrossRefGoogle Scholar
  4. 4.
    Clegg D, Reda D, Weisman M, et al.: Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthtritis Rheum 1996, 39:2004–2012.CrossRefGoogle Scholar
  5. 5.
    Dougados M, van der Linden S, Leirisalo-Repo M, et al.: Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618–627. A large study of effect of sulfasalazine in patients with spondyloarthropathy.PubMedCrossRefGoogle Scholar
  6. 6.
    de Vos M, Mielants H, Cuvelier C, et al.: Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996, 110:1696–1703.PubMedCrossRefGoogle Scholar
  7. 7.
    Levine JB, Lukawskitrubish D: Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Am 1995, 24:633–646.PubMedGoogle Scholar
  8. 8.
    Cuellar ML, Espinoza LR: Management of spondyloarthropathies. Curr Opin Rheumatol 1996, 8:288–295.PubMedCrossRefGoogle Scholar
  9. 9.
    Hawkey CJ: COX-2 inhibitors. Lancet 1999, 353:307–314.PubMedCrossRefGoogle Scholar
  10. 10.
    Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340:1888–1899.PubMedCrossRefGoogle Scholar
  11. 11.
    O’Brien J: Nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 2000, 95:1859–1861.PubMedCrossRefGoogle Scholar
  12. 12.
    Braun J, Sieper J: The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 1996, 8:275–287.PubMedCrossRefGoogle Scholar
  13. 13.
    Van den Bosch F, Kruithof E, De Vos M, et al.: Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000, 356:1821–1822.PubMedCrossRefGoogle Scholar
  14. 14.
    Sandborn W, Hanauer S: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999, 5:119–133. Extensive review of available anti-tumor necrosis factor agents.PubMedCrossRefGoogle Scholar
  15. 15.
    Schulte CMS, Dignass AU, Goebell H, et al.: Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000, 119:909–920.PubMedCrossRefGoogle Scholar
  16. 16.
    Schoon EJ, Blok BM, Geerling BJ, et al.: Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000, 119:1203–1208.PubMedCrossRefGoogle Scholar
  17. 17.
    Ghosh S, Cowen S, Hannan WJ, Ferguson A: Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994, 107:1031–1039.PubMedGoogle Scholar
  18. 18.
    Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254–1259.PubMedGoogle Scholar
  19. 19.
    Faulkner KG: Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000, 15:184–187.CrossRefGoogle Scholar
  20. 20.
    Robinson RJ, Krzywicki T, Almond L, et al.: Effect of a low-impact exercise program on bone mineral density in Crohn’s disease: a randomized controlled trial. Gastroenterology 1998, 115:36–41. Physical exercise improves bone mass density in patients with Crohn’s disease.PubMedCrossRefGoogle Scholar
  21. 21.
    Farahmand BY, Persson PG, Michaelsson K, et al.: Physical activity and hip fracture: a population-based case-control study. Swedish Hip Fracture Study Group. Int J Epidemiol 2000, 29:308–314.PubMedCrossRefGoogle Scholar
  22. 22.
    Semeao EJ, Stallings VA, Peck SN, Piccoli DA: Vertebral compression fractures in pediatric patients with Crohn’s disease. Gastroenterology 1997, 112:1710–1713.PubMedCrossRefGoogle Scholar
  23. 23.
    Clements D, Compston JE, Evans WD, Rhodes J: Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993, 34:1543–1546.PubMedGoogle Scholar
  24. 24.
    Komulainen MH, Kroger H, Tuppurainen MT, et al.: HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 1998, 31:45–54.PubMedCrossRefGoogle Scholar
  25. 25.
    Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637–645.PubMedCrossRefGoogle Scholar
  26. 26.
    Clemett D, Spencer CM: Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 2000, 60:379–411.PubMedCrossRefGoogle Scholar
  27. 27.
    Cummings SR, Palermo L, Browner W, et al.: Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000, 283:1318–1321.PubMedCrossRefGoogle Scholar
  28. 28.
    Compston J: Prevention of osteoporotic fractures in postmenopausal women. Baillieres Best Pract Res Clin Endocrinol Metab 2000, 14:251–264.PubMedCrossRefGoogle Scholar
  29. 29.
    Michaelsson K, Baron JA, Farahmand BY, et al.: Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998, 316:1853–1863.Google Scholar
  30. 30.
    Bernstein CN, Seeger LL, Anton PA, et al.: A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroidusing patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996, 10:777–786.PubMedCrossRefGoogle Scholar
  31. 31.
    Eastell R, Reid DM, Compston J, et al.: A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998, 244:271–292. An excellent review of treatment of glucocorticoid associated bone loss.PubMedCrossRefGoogle Scholar
  32. 32.
    Boutsen Y, Jamart J, Esselinckx W, et al.: Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 1997, 61:266–271.PubMedCrossRefGoogle Scholar
  33. 33.
    Friedman S, Marion JF, Scherl E, et al.: The treatment of choice for pyoderma gangrenosum complicating IBD-intravenous cyclosporin [abstract]. Gastroenterology 1997, 112:A975.CrossRefGoogle Scholar
  34. 34.
    Jolles S, Niclasse S, Benson A: Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 1999, 140:564–565.PubMedCrossRefGoogle Scholar
  35. 35.
    Nousari HC, Lynch W, Anhalt GJ, Petri M: The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 1998, 128:783–784.Google Scholar
  36. 36.
    Peuckman V, Fisch M, Bruera E: Potential novel uses of thalidomide: focus on palliative care. Drugs 2000, 60:273–292.CrossRefGoogle Scholar
  37. 37.
    Lyons JL, Rosenbaum JT: Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 1997, 115:61–64.PubMedGoogle Scholar
  38. 38.
    Rustgi AK, Marcus DM: Gastrointestinal and nutritional disorders. In Principles and Practice of Ophthalmology: Clinical Practice. Edited by Albert DM, Jacobiec FA. Philadelphia: W B Saunders Co; 1994:2975–2985.Google Scholar
  39. 39.
    Gow PJ, Chapman RW: Liver transplantation for primary sclerosing cholangitis. Liver 2000, 20:97–103.PubMedCrossRefGoogle Scholar
  40. 40.
    Graziadei IW, Wiesner RH, Marotta PJ, et al.: Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999, 30:1121–1127.PubMedCrossRefGoogle Scholar
  41. 41.
    Mitchell SA, Chapman RW: Review article: the management of primary sclerosing cholangitis. Aliment Pharmacol Ther 1997, 11:33–43.PubMedCrossRefGoogle Scholar
  42. 42.
    Poupon R, Chazouilleres O, Poupon RE: Chronic cholestatic diseases. J Hepatol 1999, 32(suppl 1):129–140.Google Scholar
  43. 43.
    Franco J: Pruritus. Curr Treat Options Gastroenterol 1999, 2:451–456.PubMedCrossRefGoogle Scholar
  44. 44.
    Shapira M, Henrion J, Ravoet C, et al.: Thromboembolism in inflammatory bowel disease. Acta Gastroenterol Belg 1999, 62:182–186.Google Scholar
  45. 45.
    Papa A, Danese S, Gasbarinni A, Gasbarrini G: Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000, 14:1403–1409.PubMedCrossRefGoogle Scholar
  46. 46.
    Pardi DS, Loftus EV, Tremaine WJ, et al.: Acute major gastrointestinal hemorrhage in inflammatory bowel disease. Gastrointest Endosc 1999, 49:153–157.PubMedCrossRefGoogle Scholar
  47. 47.
    Dekker-Saeys BJ, Dijkmans BAC, Tytgat GNJ: Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): an open trial. J Rheumatol 2000, 27:723–726.PubMedGoogle Scholar
  48. 48.
    Durez P, Horsmans Y: Dramatic response after an intravenous loading dose of azathioprine in one case of severe and refractory ankylosing spondylitis. Rheumatology (Oxford) 2000, 39:182–184.CrossRefGoogle Scholar
  49. 49.
    Matteson EL, Orces CH, Duffy J, et al.: Induction therapy with an intravenous loading dose of azathioprine for treatment of refractory, active rheumatoid arthritis. Arthritis Rheum 1999, 42:186–187.PubMedCrossRefGoogle Scholar
  50. 50.
    Suarez-Almazor ME, Spooner C, Belseck E: Azathioprine for treating rheumatoid arthritis [CD-ROM]. Oxford: Cochrane Database Syst Rev; 2000.Google Scholar
  51. 51.
    Kerstens PJ, Jeurissen ME, de Graaf R, et al.: Radiological and clinical results of longterm treatment of rheumatoid arthritis with methotrexate and azathioprine. J Rheumatol 2000, 27:1148–1155.PubMedGoogle Scholar
  52. 52.
    Henry D, Lim LL-Y, Garcia-Rodriguez LA, et al.: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996, 312:1563–1566.PubMedGoogle Scholar
  53. 53.
    Langman MJ, Jensen DM, Watson DJ, et al.: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999, 282:1929–1933.PubMedCrossRefGoogle Scholar
  54. 54.
    Laine L, Harper S, Simon T, et al.: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999, 117:776–783.PubMedCrossRefGoogle Scholar
  55. 55.
    Moreland LW, Schiff MH, Baumgartner SW, et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999, 130:478–486.PubMedGoogle Scholar
  56. 56.
    Weinblatt ME, Kremer JM, Bankhurst AD, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253–259.PubMedCrossRefGoogle Scholar
  57. 57.
    Furst DE, Breedveld FC, Burmester GR, et al.: Updated consensus statement on tumour necrosis blocking agents for the treatment of rheumatoid arthritis. Ann Rheum Dis 2000, 59(suppl 1):I1–2.PubMedCrossRefGoogle Scholar
  58. 58.
    Lipsky PE, van der Heyde DM, St Clair EW, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 434:1594–1602.CrossRefGoogle Scholar
  59. 59.
    Anis AH, Tugwell PX, Wells GA, Stewart DG: A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. J Rheumatol 1996, 23:609–616.PubMedGoogle Scholar
  60. 60.
    Goldblum R: Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993, 11(suppl 8):S117–119.PubMedGoogle Scholar
  61. 61.
    Huizinga TWJ, Dijkmans BAC, van der Velde EA, et al.: An open study of pentoxifylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 1996, 55:833–836.PubMedCrossRefGoogle Scholar
  62. 62.
    Keesal N, Wasserman MJ, Bookman A, et al.: Thalidomide in the treatment of refractory rheumatoid arthritis. J Rheumatol 1999, 26:2344–2347.PubMedGoogle Scholar
  63. 63.
    Oliver SJ, Freeman SL, Corral LG, et al.: Thalidomide analogue CC069 inhibits development of rat adjuvant arthritis. Clin Exp Immunol 1999, 118:315–321.PubMedCrossRefGoogle Scholar
  64. 64.
    Vogelsang H, Ferenci P, Resch H, et al.: Prevention of bone mineral loss in patients with Crohn’s disease by long-term oral vitamin D supplementation. Eur J Gastroenterol 1995, 7:609–614.Google Scholar
  65. 65.
    Vogelsang H, Ferenci P, Schilling R, et al.: Vitamin D status in outpatients with Crohn’s disease. Eur J Gastroenterol Hepatol 1994, 6:513–517.CrossRefGoogle Scholar
  66. 66.
    Black DM, Cummings SR, Karpft DB, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: results from the Fracture Intervention Trial Research Group. Lancet 1996, 348:1535–1541.PubMedCrossRefGoogle Scholar
  67. 67.
    Cummings SR, Black DM, Thompson DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077–2082.PubMedCrossRefGoogle Scholar
  68. 68.
    Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344–1352.PubMedCrossRefGoogle Scholar
  69. 69.
    Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000, 11:83–91.CrossRefGoogle Scholar
  70. 70.
    Reid IR, King AR, Alexander CJ, Ibbertson HK: Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988, 1:143–146.PubMedCrossRefGoogle Scholar
  71. 71.
    Adachi JD, Bensen WG, Brown J, et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382–387.PubMedCrossRefGoogle Scholar
  72. 72.
    Haderslev KV, Tjellesen L, Sorensen HA, Staun M: Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease. Gastroenterology 2000, 119:639–646. A small, though interesting, study of bisphosphonate use in patients with IBD.PubMedCrossRefGoogle Scholar
  73. 73.
    Lanza FL, Hunt RH, Thomson ABR, et al.: Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000, 119:631–638.PubMedCrossRefGoogle Scholar
  74. 74.
    Lanza FL, Rack MF, Li Z, et al.: Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs aspirin in healthy postmenopausal women. Aliment Pharmacol Ther 2000, 14:1663–1670.PubMedCrossRefGoogle Scholar
  75. 75.
    Cummings SR, Eckert S, Krueger KA, et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281:2189–2197.PubMedCrossRefGoogle Scholar
  76. 76.
    Cranney A, Welch V, Adachi JD, et al.: Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis [CD-ROM]. Oxford: Cochrane Database Syst Rev; 2000.Google Scholar
  77. 77.
    Chesnut CH, Silverman S, Andriano K, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000, 109:267–276.PubMedCrossRefGoogle Scholar
  78. 78.
    Downs RWJ, Bell NH, Ettinger MP, et al.: Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000, 85:1783–1788. Comparison between efficacy of a bisphosphonate versus calcitonin in treatment of osteoporosis.PubMedCrossRefGoogle Scholar
  79. 79.
    von Tirpitz C, Klaus J, Bruckel J, et al.: Increase of bone mineral density with sodium fluoride in patients with Crohn’s disease. Eur J Gastroenterol Hepatol 2000, 12:19–24.CrossRefGoogle Scholar
  80. 80.
    Gilbert AM, Caltabiano S, Roberts D, et al.: Novel and selective calcitonin inducing agents. J Med Chem 2000, 43:1233–1233.Google Scholar
  81. 81.
    Whitfield J, Morley P, Willick G: The parathyroid hormone, its fragment and analogues-potent bonebuilders for treating osteoporosis. Expert Opin Invest Drugs 2000, 9:1293–1315.CrossRefGoogle Scholar
  82. 82.
    Giannotti B, Pimpineli N: Topical corticosteroids. Which drug and when? Drugs 1992, 44:65–71.PubMedGoogle Scholar
  83. 83.
    D’Inca R, Fagiuoli S, Sturniolo GC: Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. Ann Intern Med 1998, 128:783–784.PubMedGoogle Scholar
  84. 84.
    Matis WL, Ellis CN, Griffiths CEM, Lazarus GS: Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992, 128:1060–1064.PubMedCrossRefGoogle Scholar
  85. 85.
    Carp JM, Onuma E, Das K, Gottlieb AB: Intravenous cyclosporine therapy in the treatment of pyoderma gangrenosum secondary to Crohn’s disease. Cutis 1997, 60:135–138.PubMedGoogle Scholar
  86. 86.
    Schuppe HC, Homey B, Assman T, et al.: Topical treatment for pyoderma gangrenosum. Lancet 1998, 351:831.CrossRefGoogle Scholar
  87. 87.
    Richter-Hintz D, Schuppe HC, Homey B, et al.: Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum. J Am Acad Dermatol 2000, 42:304–305.PubMedCrossRefGoogle Scholar
  88. 88.
    Nasr IS: Topical tacrolimus in dermatology. Clin Exp Dermatol 2000, 25:250–254.PubMedCrossRefGoogle Scholar
  89. 89.
    Hughes AP, Jackson JM, Callen JP: Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000, 284:1546–1548.PubMedCrossRefGoogle Scholar
  90. 90.
    Cliff S, Holden CA, Thomas PR, et al.: Split skin grafts in the treatment of pyoderma gangrenosum. A report of four cases. Dermatol Surg 1999, 25:299–302.PubMedCrossRefGoogle Scholar
  91. 91.
    Alam M, Grossman ME, Schneiderman PI, et al.: Surgical management of pyoderma gangrenosum: case report and review. Dermatol Surg 2000, 26:1063–1066.PubMedCrossRefGoogle Scholar
  92. 92.
    Wintzen M, Wensveen CAH, van der Schaar PJ, et al.:Fulminante pyoderma gangrenosum bij patiente met morbus Crohn succesvol behandeld met anti-TNF-alpha. Ned Tijdschr Dermatol Venereol 2001, In press.Google Scholar
  93. 93.
    Groves RW, Schmidt-Lucke JA: Recombinant human Gm-CSF in the treatment of poorly healing wounds. Adv Skin Wound Care 2000, 13:107–112.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Ad A. van Bodegraven
    • 1
  • Ben A. C. Dijkmans
    • 1
  • Paul Lips
    • 1
  • Tom J. Stoof
    • 1
  • A. Salvador Peña
    • 1
  • Stephan G. M. Meuwissen
    • 1
  1. 1.Department of GastroenterologyAcademic Hospital Free UniversityAmsterdamThe Netherlands

Personalised recommendations